The side effects of hormonal therapy at the patients with prostate cancer

Wspolczesna Onkologia

Volumn 16, Issue 6, 2012, Pages 491-497

  Ziółkowska, Ewa ^a   Zarzycka, Małgorzata ^a   Wiśniewski, Tomasz ^a,b   Zyromska, Agnieszka ^a  

^a Regional Oncology Centre Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Androgen deprivation therapy; Prostate cancer; Side effects

Indexed keywords

ALCOHOL; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CITALOPRAM; CLONIDINE; CYPROTERONE; DENOSUMAB; DIETHYLSTILBESTROL; ESTROGEN; GABAPENTIN; MEGESTROL; NADROXYPROGESTERONE; PAMIDRONIC ACID; PHOSPHODIESTERASE; PLACEBO; RALOXIFENE; TESTOSTERONE; UNCLASSIFIED DRUG; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL OBESITY; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BODY POSITION; BONE DENSITY; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COFFEE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; FATIGUE; FOOD INTAKE; FRAGILITY FRACTURE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART INFARCTION; HEAT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IMPOTENCE; LUMBAR VERTEBRA; MENTAL DETERIORATION; MENTAL INSTABILITY; METABOLIC DISORDER; MOOD DISORDER; MUSCLE ATROPHY; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT MONITORING; PHYSICAL ACTIVITY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SMOKING; SPINE FRACTURE; STRESS; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 84872575163     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.32478     Document Type: Review

References (47)

1. Krajowy Rejestr Nowotworów. Available at: http://85.128.14.124/ krn.
2. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60: 7-11.
3. Borowka A, Dobruch J, Chłosta P. Leczenie hormonalne chorych na raka gruczołu krokowego. Przegl Urol 2011; 12: 23-32.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44. (Pubitemid 41043794)
5. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8.
6. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-7. (Pubitemid 41759293)
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465-71.
8. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61. (Pubitemid 351439226)
9. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56. (Pubitemid 46630983)
10. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998; 91: 855-7.
11. Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int 2009; 83: 373-8.
12. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006; 33: 181-90.
13. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98: 20-7. (Pubitemid 43890697)
14. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 2005; 23: 3830-42.
15. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64. (Pubitemid 40096612)
16. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903. (Pubitemid 46657388)
17. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80.
18. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006; 40: 2107-14. (Pubitemid 44954427)
19. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8.
20. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449-52.
21. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005; 32: 589-603.
22. López AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16: 707-11. (Pubitemid 40897469)
23. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7.
24. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-6. (Pubitemid 28465474)
25. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24-34.
26. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-na?ve men with prostate carcinoma. Cancer 2001; 91: 2238-45. (Pubitemid 32552808)
27. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-66. (Pubitemid 47285316)
28. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55.
29. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol 2003; 169: 2008-12. (Pubitemid 36576705)
30. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176: 972-8. (Pubitemid 44142571)
31. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-24. (Pubitemid 351650576)
32. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5: 271-7. (Pubitemid 46867363)
33. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-42. (Pubitemid 46596753)
34. Scherr D, Pitts WR Jr, Vaughn ED Jr. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167: 535-8. (Pubitemid 34074522)
35. Taxel P, Fall PM, Albertsen PC, Dowsett RD, Trahiotis M, Zimmerman J, Ohannessian C, Raisz LG. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002; 7: 4907-13. (Pubitemid 35316324)
36. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-6. (Pubitemid 39071482)
37. Smith MR, Egerdie B, Hernández Toriz N, et al.; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55.
38. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 9768: 813-22.
39. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen- deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-9. (Pubitemid 38222847)
40. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93: 2042-9. (Pubitemid 351831513)
41. Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86: 5108-17. (Pubitemid 33070222)
42. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83. (Pubitemid 46630747)
43. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16. (Pubitemid 35403784)
44. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5. (Pubitemid 46999213)
45. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; And the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-500. (Pubitemid 47463063)
46. Garnick MB, Pratt CM, Campion M, Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: Phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (14S): 4578.
47. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-5. (Pubitemid 38479421)